Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1626 1627 1674
This examiner grants 51% of resolved cases
Jackson J. Hernandez is an examiner in Art Unit 1600, part of Tech Center 1600. He has managed 70 resolved cases, providing a sufficient sample to identify his prosecution trends. His allowance rate is 51.4 percent, which suggests a balanced environment for applicants. This 51.4 percent rate indicates that about half of the applications he reviews are granted, requiring a focused and effective prosecution strategy. The 70 resolved cases establish an initial baseline for evaluating his examination style in Art Unit 1600.
The interview lift of 45.0 percent is a very strong positive sign for applicants. This lift suggests that direct communication with the examiner can significantly improve the chances of obtaining an allowance compared to the 51.4 percent baseline. By conducting an interview, practitioners can address the examiner's concerns more directly and potentially find a path to allowable subject matter. The 45.0 percent lift is a highly valuable data point for strategic planning in Tech Center 1600.
The median days to allowance for applications under his review is 1214. This timeline is a useful benchmark for managing expectations regarding the duration of the patent process. The 1214-day median pendency, combined with the 51.4 percent allowance rate, highlights the importance of using tools like the 45.0 percent interview lift to navigate the process. The 1214-day duration is a key metric for long-term planning in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18205841 | LIGAND-POLAR DRUG CONJUGATES | Non-Final OA | Tripartite Therapeutics Inc. |
| 18028311 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | Final Rejection | The Regents of the University of California |
| 18022017 | BIOINSPIRED LIPID DERIVATIVES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18015387 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Non-Final OA | Merck Sharp & Dohme LLC |
| 17917538 | COMPOSITIONS AND METHODS TO INHIBIT FOULING OF AMMONIUM SALTS | Final Rejection | ECOLAB USA INC. |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | Non-Final OA | The General Hospital Corporation |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | Final Rejection | Novartis AG |
| 18468907 | C19 SCAFFOLDS AND STEROIDS AND METHODS OF USE AND MANUFACTURE THEREOF | Non-Final OA | Trustees of Dartmouth College |
| 18987316 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18843615 | AGRICULTURE COMPOSITION | Non-Final OA | Nippon Kayaku Kabushiki Kaisha |
| 18020025 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Final Rejection | CORNELL UNIVERSITY |
| 18020019 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Final Rejection | CORNELL UNIVERSITY |
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18084092 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | Final Rejection | Janssen Pharmaceutica NV |
| 18262493 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Final Rejection | HiberCell, Inc. |
| 18033931 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Final Rejection | Blueprint Medicines Corporation |
| 18285915 | METHOD FOR PREPARING DEUTERATED CHEMICAL BY MEANS OF DEUTERATION REACTION OF CARBON-HYDROGEN BOND WITH DEUTERIUM GAS UNDER CATALYSIS OF ALKALI | Non-Final OA | FUDAN UNIVERSITY |
| 18028463 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | Final Rejection | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18784201 | METHODS OF TREATING ESTROGEN SENSITIVE DISEASES WITH CANNABIS EXTRACT | Non-Final OA | The University of Newcastle |
| 18725070 | PREPARATION OF A COMPOUND FOR THE TREATMENT OF GOUT OR HYPERURICEMIA | Non-Final OA | Arthrosi Therapeutics, Inc. |
| 18007983 | PURINES AND METHODS OF THEIR USE | Final Rejection | Kineta, Inc. |
| 18255134 | BICYCLIC DERIVATIVES | Final Rejection | ELANCO TIERGESUNDHEIT AG |
| 18015396 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | Non-Final OA | Servier Pharmaceuticals LLC |
| 18005004 | DERIVATIVES OF 2-OXO-N-(4-(PYRIMIDIN-4-YLOXY/THIO)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE FOR USE AS PROTEIN KINASE INHIBITORS FOR THERAPY | Final Rejection | AUCENTRA THERAPEUTICS PTY LTD |
| 17252255 | Ionic Liquid Preparation | Final Rejection | Seren Technologies Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy